Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial
Abstract
Oral lichen planus (OLP) is a T‐cell‐mediated disease characterized by immune‐mediated basal cell degeneration releasing interleukins (ILs) such as IL‐6 and IL‐8 into the circulation. Their serum levels reportedly reflect disease activity. Although many therapeutic options are available, none are curative. We compared the efficacy of tacrolimus 0.1% ointment and pimecrolimus 1% cream in OLP and correlated with serum IL‐6 and IL‐8 levels before and after treatment. Forty patients with symptomatic OLP were randomized into two groups, to receive either topical tacrolimus 0.1% ointment or pimecrolimus 1%...
Source: International Journal of Dermatology - July 3, 2015 Category: Dermatology Authors: Suruchi Vohra, Archana Singal, Suman Bala Sharma Tags: Clinical Trial Source Type: research
Topical tacrolimus for atopic dermatitis.
CONCLUSIONS: Tacrolimus 0.1% was better than low-potency corticosteroids pimecrolimus 1% and tacrolimus 0.03%. Results were equivocal when comparing both dose formulations to moderate-to-potent corticosteroids. Tacrolimus 0.03% was superior to mild corticosteroids and pimecrolimus. Both tacrolimus formulations seemed to be safe, and no evidence was found to support the possible increased risk of malignancies or skin atrophy with their use. The reliability and strength of the evidence was limited by the lack of data; thus, findings of this review should be interpreted with caution. We did not evaluate costs.
PMID: 2...
Source: Cochrane Database of Systematic Reviews - July 1, 2015 Category: Journals (General) Authors: Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM Tags: Cochrane Database Syst Rev Source Type: research
Reassurance About Topical Calcineurins in Children
The topical calcineurin inhibitors tacrolimus and pimecrolimus are useful and effective anti-inflammatory immunomodulator adjuncts in managing atopic dermatitis (AD). Unfortunately, because of the increased risk of lymphoma in transplant recipients receiving systemic tacrolimus and because of malignant neoplasms in animal studies with pimecrolimus, their use as topical agents has raised concerns. Yet the topical use of these drugs in humans since the mid-1990s has not appeared to cause any clear immunosuppressive propensity toward malignancy. (Source: JAMA Dermatology)
Source: JAMA Dermatology - June 1, 2015 Category: Dermatology Source Type: research
Malignancy and Topical Use of Pimecrolimus
According to this longitudinal cohort study, it seems unlikely that topical pimecrolimus as it was used in the Pediatric Eczema Elective Registry cohort to treat atopic dermatitis is associated with an increased risk of malignancy. See the Editorial by Hanifin. (Source: JAMA Dermatology)
Source: JAMA Dermatology - June 1, 2015 Category: Dermatology Source Type: research
Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis
Conclusions: Pimecrolimus was similar to tacrolimus in both efficacy and safety for AD in children, but both were better than vehicles.Dermatology (Source: Dermatology)
Source: Dermatology - May 30, 2015 Category: Dermatology Source Type: research
